Lakefront Biotherapeutics NV (LKFT.AS) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. LKFT.AS files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.84% | 30.00% | Pass |
| Interest-bearing investments | 182.79% | 30.00% | Fail |
| Non-permissible income | 4.17% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.41% | 33.00% | Pass |
| Interest-bearing investments | 88.01% | 33.00% | Fail |
| Non-liquid assets | 11.71% | at least 20.00% | Fail |
| Non-permissible income | 4.17% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.41% | 33.33% | Pass |
| Cash + interest-bearing securities | 88.01% | 33.33% | Fail |
| Accounts receivable | 88.29% | 33.33% | Fail |
| Non-permissible income | 4.17% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.41% | 33.33% | Pass |
| Cash + interest-bearing securities | 88.01% | 33.33% | Fail |
| Accounts receivable | 88.29% | 50.00% | Fail |
| Non-permissible income | 4.17% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.76% | 33.00% | Pass |
| Cash + interest-bearing securities | 164.88% | 33.00% | Fail |
| Accounts receivable | 0.53% | 33.00% | Pass |
| Non-permissible income | 4.17% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.72% | 33.00% | Pass |
| Cash + interest-bearing securities | 156.57% | 49.00% | Fail |
| Accounts receivable | 0.50% | 49.00% | Pass |
| Non-permissible income | 4.17% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.72% | 33.33% | Pass |
| Cash + interest-bearing securities | 156.57% | 33.33% | Fail |
| Accounts receivable | 157.07% | 49.00% | Fail |
| Non-permissible income | 4.17% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 38.10 | NEUTRAL |
| Stochastic %K (14) | 6.40 | BUY |
| CCI (20) | -155.61 | BUY |
| Williams %R (14) | -93.60 | BUY |
| MACD (12,26,9) | -0.17 | SELL |
| ROC (10) | -7.83 | SELL |
| Momentum (10) | -1.98 | SELL |
| EMA (10) | 24.13 | SELL |
| SMA (10) | 24.34 | SELL |
| EMA (20) | 24.35 | SELL |
| SMA (20) | 24.54 | SELL |
| EMA (30) | 24.45 | SELL |
| SMA (30) | 24.22 | SELL |
| EMA (50) | 24.59 | SELL |
| SMA (50) | 24.81 | SELL |
| EMA (100) | 24.96 | SELL |
| SMA (100) | 24.59 | SELL |
| EMA (200) | 26.03 | SELL |
| SMA (200) | 26.06 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2025-12-31, figures in EUR.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.